Please assess the completion status of the following clinical trial:

Trial Title: (H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is between 25 and 70 years of age (inclusive) at the time of randomization.~* Subject is an appropriate candidate for H.E.L.P. apheresis treatment for hypercholesterolemia according to current Plasmat® Secura approval criteria.~* Subject has received a minimum of two consecutive bi-monthly\* H.E.L.P. apheresis treatments using the Plasmat® Secura apheresis system \>30 days prior to the screening visit.~* Subject is willing to maintain cholesterol lowering dietary and drug therapies as prescribed through the course of the study.~* Subject is willing and able to provide written informed consent and Health Insurance Portability and Accountability Act (HIPAA) Waiver.~* Sterile, post-menopausal, or using acceptable birth control for the duration of the study. Acceptable birth control is defined as having a vasectomized, postmenopausal, or sterile partner; the ongoing use of approved hormonal contraceptives, barrier method, or an intrauterine device; or abstinence.~  * Every 14 days (±2 days)~Exclusion Criteria:~* A History of a known sensitivity to heparin or ethylene oxide.~* A history of hemorrhagic diathesis, bleeding/clotting disorder, thrombocytopenia (defined as platelet count \< 150 x109/L), or for whom the use of heparin would cause excessive or uncontrolled anticoagulation or for whom adequate anticoagulation cannot be safely achieved (ie., hemophilia, recent surgery, acute internal bleeding, gastrointestinal ulcers).~* Females who are pregnant or lactating.~* Subjects\< 106 lbs. or \<48.2 kg in body weight; or whose weight is \>1.5 times their ideal weight.~* Certain cardiac impairments such as congestive heart failure, major arrhythmia, or diastolic blood pressure greater than 100 mm/Hg on two separate occasions at least 24 hours apart.~* Renal insufficiency defined as creatinine greater \>2.0 mg/dlL or is dependent upon renal dialysis.~* Untreated hypothyroidism; uncontrolled diabetes mellitus; or fasting triglycerides \>500 mg/dL.~* Serious systemic disease (e.g., advanced neoplasms, and acute hepatitis) including Immune system suppression or compromise, that could preclude survival to study completion.~* History of stroke within 6 months of the screening visit.~* Received thrombolytic treatment \< 7 days of screening.visit.~* Taken or requires a prohibited treatment \< 30 days prior to the Screening Visit, or requires a prohibited treatment at anytime during the course of the study.~* Neutropenia (neutrophil count \< 0.5 x109/L).~* History of liver disease or serum ALT and/or AST \> 2X upper limit of normal range.~* History of dementia.~* History of anemia (value outside the lower normal range).~* acetyl salicylic acid (ASA) \> 325 mg/day.~* Subject currently enrolled in another investigational study (does not apply to PMS for Secura device).~* Subject with any other medical condition that in the opinion of the investigator might put the subject at risk or interfere with his/her participation.~* Subject is unwilling or unable to comply with the protocol or to cooperate fully with the investigator or site personnel.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A (Secura then Futura) (Type: OTHER): The Group Randomized first to the approved Plasmat® Secura apheresis system and then to the Plasmat® Futura apheresis system.
- B (Futura then Secura) (Type: OTHER): The Group Randomized first to the approved Plasmat® Futura apheresis system and then to the Plasmat® Secura apheresis system.

Based on this trial design, predict the completion outcome and termination type (if applicable).